Literature DB >> 26279024

Imaging Changes in Pediatric Intracranial Ependymoma Patients Treated With Proton Beam Radiation Therapy Compared to Intensity Modulated Radiation Therapy.

Jillian R Gunther1, Mariko Sato2, Murali Chintagumpala2, Leena Ketonen3, Jeremy Y Jones4, Pamela K Allen1, Arnold C Paulino5, M Fatih Okcu2, Jack M Su2, Jeffrey Weinberg6, Nicholas S Boehling1, Soumen Khatua7, Adekunle Adesina8, Robert Dauser9, William E Whitehead9, Anita Mahajan10.   

Abstract

PURPOSE: The clinical significance of magnetic resonance imaging (MRI) changes after radiation therapy (RT) in children with ependymoma is not well defined. We compared imaging changes following proton beam radiation therapy (PBRT) to those after photon-based intensity modulated RT (IMRT). METHODS AND MATERIALS: Seventy-two patients with nonmetastatic intracranial ependymoma who received postoperative RT (37 PBRT, 35 IMRT) were analyzed retrospectively. MRI images were reviewed by 2 neuroradiologists.
RESULTS: Sixteen PBRT patients (43%) developed postradiation MRI changes at 3.8 months (median) with resolution by 6.1 months. Six IMRT patients (17%) developed changes at 5.3 months (median) with 8.3 months to resolution. Mean age at radiation was 4.4 and 6.9 years for PBRT and IMRT, respectively (P = .06). Age at diagnosis (>3 years) and time of radiation (≥3 years) was associated with fewer imaging changes on univariate analysis (odds ratio [OR]: 0.35, P = .048; OR: 0.36, P = .05). PBRT (compared to IMRT) was associated with more frequent imaging changes, both on univariate (OR: 3.68, P = .019) and multivariate (OR: 3.89, P = .024) analyses. Seven (3 IMRT, 4 PBRT) of 22 patients with changes had symptoms requiring intervention. Most patients were treated with steroids; some PBRT patients also received bevacizumab and hyperbaric oxygen therapy. None of the IMRT patients had lasting deficits, but 2 patients died from recurrent disease. Three PBRT patients had persistent neurological deficits, and 1 child died secondarily to complications from radiation necrosis.
CONCLUSIONS: Postradiation MRI changes are more common with PBRT and in patients less than 3 years of age at diagnosis and treatment. It is difficult to predict causes for development of imaging changes that progress to clinical significance. These changes are usually self-limiting, but some require medical intervention, especially those involving the brainstem.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26279024     DOI: 10.1016/j.ijrobp.2015.05.018

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  31 in total

1.  Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.

Authors:  Lindsay M Morton; Luisel Ricks-Santi; Catharine M L West; Barry S Rosenstein
Journal:  Int J Part Ther       Date:  2018-09-21

2.  Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma.

Authors:  Alexander L Chin; Everett J Moding; Sarah S Donaldson; Iris C Gibbs; Scott G Soltys; Susan M Hiniker; Erqi L Pollom
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

Review 3.  Treatment planning for proton therapy: what is needed in the next 10 years?

Authors:  Hakan Nystrom; Maria Fuglsang Jensen; Petra Witt Nystrom
Journal:  Br J Radiol       Date:  2019-08-07       Impact factor: 3.039

4.  Linear energy transfer incorporated intensity modulated proton therapy optimization.

Authors:  Wenhua Cao; Azin Khabazian; Pablo P Yepes; Gino Lim; Falk Poenisch; David R Grosshans; Radhe Mohan
Journal:  Phys Med Biol       Date:  2017-12-19       Impact factor: 3.609

Review 5.  Particle Radiation Induced Neurotoxicity in the Central Nervous System.

Authors:  David R Grosshans; Joseph G Duman; M Waleed Gaber; Gabriel Sawakuchi
Journal:  Int J Part Ther       Date:  2018-09-21

Review 6.  Radiobiological issues in proton therapy.

Authors:  Radhe Mohan; Christopher R Peeler; Fada Guan; Lawrence Bronk; Wenhua Cao; David R Grosshans
Journal:  Acta Oncol       Date:  2017-08-22       Impact factor: 4.089

Review 7.  Charged-particle therapy in cancer: clinical uses and future perspectives.

Authors:  Marco Durante; Roberto Orecchia; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2017-03-14       Impact factor: 66.675

8.  Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma.

Authors:  Christopher R Peeler; Dragan Mirkovic; Uwe Titt; Pierre Blanchard; Jillian R Gunther; Anita Mahajan; Radhe Mohan; David R Grosshans
Journal:  Radiother Oncol       Date:  2016-11-16       Impact factor: 6.280

Review 9.  Proton therapy for paediatric CNS tumours - improving treatment-related outcomes.

Authors:  Vinai Gondi; Torunn I Yock; Minesh P Mehta
Journal:  Nat Rev Neurol       Date:  2016-05-20       Impact factor: 42.937

Review 10.  Biology and management of ependymomas.

Authors:  Jing Wu; Terri S Armstrong; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-03-28       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.